Ger Brophy is the Interim Chief Executive Officer of ElevateBio and a member of its Board of Directors. He previously served as a strategic advisor to the Company’s leadership team and CEO.
by
Management Team
Bhakti has more than 20 years of experience in biotech, consulting, and financial services including corporate finance, business development, strategy, and business process re-engineering. Bhakti joined ElevateBio as one of earliest employees and has been leading the finance team since 2018.
Jacob Abrams joined ElevateBio in 2020, and as general counsel, he leads the Company’s legal function.
Catherine Hu joined ElevateBio in 2021 to lead the Company’s investor relations and corporate affairs functions. Prior to ElevateBio, Catherine led investor relations, corporate affairs, and patient advocacy functions at Scholar Rock, Inc. and was part of the investor relations team at Alexion Pharmaceuticals.
Missy has more than 15 years of experience in operations and people strategies. As a strategic thought partner to the leadership team, she identifies areas for operational improvement, provides insight and analysis on company strategy and operations, and ensures a continued focus on top priorities across the company.
Larry has more than 20 years of leadership experience and deep technical expertise, with proven success in building and scaling commercial teams, driving revenue growth, and establishing global partnerships. Currently, Larry is the Chief Commercial Officer at ElevateBio where he leads commercial strategy to accelerate revenue growth by expanding partnerships across ElevateBio’s BaseCamp manufacturing and Life Edit gene editing businesses.
Aaron Nudelman joined ElevateBio in 2020, and as SVP, Head of Intellectual Property, he leads the Company’s IP function overseeing patent preparation, prosecution, maintenance, and enforcement; IP diligence and strategy; and IP aspects of license negotiation and related transactions.
Michael has spent the last twenty years in biotechnology building, leading and motivating process development and manufacturing teams to support clinical programs from early development to late-stage clinical trials. Currently, Michael is the Chief Technology Officer at ElevateBio BaseCamp and is responsible for BaseCamp’s technology offerings, including cell therapy, LentiPeakTM platform, and process development.
Bryan Rizzo joined ElevateBio in 2025 and as Senior Vice President, Head of Quality, he is responsible for overseeing the harmonization of quality operations across multiple cell and gene therapy research and manufacturing locations. He ensures regulatory compliance and risk-based decision-making within scalable and sustainable processes across the organization.
Amy leads research and development at Life Edit Therapeutics. She has more than 20 years of scientific leadership and expertise with an extensive background in genetic medicine, neuroscience, drug development, and scientific strategy.
Heidi Wagner leads the Company’s global government affairs function, playing a key role in the continued national and global expansion of our technology platforms and biomanufacturing network. Heidi has more than 20 years of experience in establishing and executing global strategies across government affairs, public policy, and patient advocacy.
